

KBP Biosciences is a global, clinical stage biopharmaceutical company focused on the research and development of new chemical entities with known mechanisms of action targeting underserved patient populations.

- Headquartered in Princeton, NJ
- Strong capabilities from Discovery and CMC through global clinical development and registration
- Primarily focused on three therapeutic areas:
 - Major organ protection
 - Anti-infectives
 - Inflammation


Lead program in hypertension – multi-billion dollar opportunity – KBP-5074

- Non-steroidal mineralocorticoid receptor antagonist (MRA)
- Treatment of uncontrolled hypertension in patients with moderate to severe Chronic Kidney Disease
- Potentially best-in-class safety and efficacy.
- Being studied in a Phase 2b trial, with data expected in 4Q 2020.

China-focused anti-infective program – \$500-700 million dollar opportunity – KBP-7072

- Third generation aminomethylcycline
- For treatment of multiple strains of drug resistant infections
- High activity against certain key pathogens, including *Acinetobacter baumannii*.
- Development program is largely funded by government grants and other non-dilutive capital.

Robust Clinical and Preclinical Pipeline



Hypertension in Advanced CKD: Large Market With Major Unmet Need

There are an estimated 43 million advanced CKD patients across the US, China and Europe, of whom nearly 60% (~25m) have uncontrolled hypertension. Despite a proven ability to reduce blood pressure, MRAs are only used in 17-18% of patients, due to high risk of Hyperkalemia. These patients, who often present with multiple comorbidities, have few if any viable treatment options.

Compound	MR IC50 (nM)	T ½ - h	Hypertension Reduction	Kidney Protection	Non-Steroidal	Avoids Hyperkalemia
KBP-5074	2.70	50-60 h	✓	✓	✓	✓
Spironolactone	14.3	1.4 h	✓	✓	✗	✗
Finerenone	18	2-3 h	✗	✓	✓	✓
Eplerenone	268	3-6 h	✓	✓	✗	✗

Sophisticated R&D Engine to Fuel Innovation and Pipeline Expansion

KBP has built a proprietary R&D platform aimed at the discovery and development of global first-in-class compounds. The platform includes a compound library which is the basis of new compound discovery, a bacterium library aimed at multi-drug resistant bacteria, and an in vivo pharmacology platform for screening and testing new compounds. KBP Biosciences is actively seeking to identify additional promising therapeutic opportunities and further develop its product portfolio.

Experienced Management Team with Global Expertise

Zhenhua Huang Ph.D.

Executive Chairman



Nick Hart, BA, FCMA

Chief Financial Officer



James McCabe M.D.

VP, Clinical & Medical Affairs



Thijs Spoor BPhm, MBA

Chief Executive Officer



Fred Yang Ph.D.

Chief Development Officer



Jay (Xu-Jie) Zhang M.D., Ph.D.

VP, Biology



116 Village Blvd., Suite 210 Princeton, NJ 08540 | www.kbpbiosciences.com



Follow us on Twitter
@KBPBio



Connect with us on LinkedIn
@KBP-Biosciences